roche glp 1 drug obesity shows 22.5% weight loss as it seeks to catch up with Lilly, Novo Readout Newsletter: Roche, Vertex, and

Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation

Improved Lipid and Metabolic Markers : Experimental observations with Tesamorelin have reported reductions in triglycerides , total cholesterol, and non-HDL cholesterol, alongside improved adiponectin signaling

Survodutide (BI 456906) is a GLP-1/glucagon co-agonist which has progressed to phase 3 clinical trials as treatment for obesity (SYNCHRONIZE programme)

Glutathione plays a key role in helping the liver process and remove toxins such as alcohol byproducts, medications, and environmental pollutants

Webmd.com